Davide Ceccato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Davide Ceccato has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Paolo Prandoni
Arianna Foundation on Anticoagulation, Bologna, Italy
2 shared publicationsRaffaele Pesavento
Department of Internal Medicine, University of Padova, Padua, Italy
2 shared publicationsRoberto Vettor
Department of Internal Medicine, University of Padova, Padua, Italy
2 shared publicationsAngelo Di Vincenzo
Department of Internal Medicine, University of Padova, Padua, Italy
1 shared publication- Angelo Di Vincenzo
Department of Medicine, University of Padova, Padova, Italy
1 shared publication - Chiara Simion
UO Thromboembolic Disease, Azienda Ospedaliera di Padova, Via Giustiniani 2, 35128 Padova, Italy
1 shared publication
Latest Publications
- 11 March 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 125, 137-138
Chronic limb-threatening ischemia with no revascularization option: Result from a multidisciplinary care model
- 11 March 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 125, 137-138
Chronic limb-threatening ischemia with no revascularization option: Result from a multidisciplinary care model
- 26 April 2023
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 56 (1) , 207-209
The hazard of therapeutic doses of anticoagulants in patients with isolated subsegmental pulmonary embolism
- 26 April 2023
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 56 (1) , 207-209
The hazard of therapeutic doses of anticoagulants in patients with isolated subsegmental pulmonary embolism
- Open Access
Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project
Extended-phase anticoagulation with direct oral Xa inhibitors (OAXI) is suggested in patients with cancer-associated venous thromboembolism (CAT). We report on patients enrolled in the MAC (Monitoring AntiCoagulants) Project, given rivaroxaban as extended-phase anticoagulation after CAT. The primary efficacy outcome was the incidence of symptomatic recurrent VTE; the primary safety outcomes were incidence of major and non-major clinically relevant bleeding, adverse events, and all-cause mortality. The mean patients’ follow-up was 19 months (SD 16); 64/604 (11%) had CAT. Recurrent VTE occurred in 9.3% and in 8.1% of patients with and without CAT (OR 1.2, 95% CI 0.5 to 2.9; p = 0.6). Major bleeding occurred in 4.7% and in 2.6%, respectively (OR = 1.8, 95% CI 0.5 to 6.6, p = 0.4), and non-major clinically-relevant bleeding in 4.7% and in 4.1% (OR = 1.2, 95% CI 0.3 to 3.9, p = 0.7). The relative figures for fatal haemorrhage and all-cause death were 1.6% versus 0%, and 1.6% versus 0.4%. Rivaroxaban appears to be effective and safe as extended-phase anticoagulation in patients with CAT. The mean treatment period was 3-times the standard 6-month course.
Open AccessSafety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project
Extended-phase anticoagulation with direct oral Xa inhibitors (OAXI) is suggested in patients with cancer-associated venous thromboembolism (CAT). We report on patients enrolled in the MAC (Monitoring AntiCoagulants) Project, given rivaroxaban as extended-phase anticoagulation after CAT. The primary efficacy outcome was the incidence of symptomatic recurrent VTE; the primary safety outcomes were incidence of major and non-major clinically relevant bleeding, adverse events, and all-cause mortality. The mean patients’ follow-up was 19 months (SD 16); 64/604 (11%) had CAT. Recurrent VTE occurred in 9.3% and in 8.1% of patients with and without CAT (OR 1.2, 95% CI 0.5 to 2.9; p = 0.6). Major bleeding occurred in 4.7% and in 2.6%, respectively (OR = 1.8, 95% CI 0.5 to 6.6, p = 0.4), and non-major clinically-relevant bleeding in 4.7% and in 4.1% (OR = 1.2, 95% CI 0.3 to 3.9, p = 0.7). The relative figures for fatal haemorrhage and all-cause death were 1.6% versus 0%, and 1.6% versus 0.4%. Rivaroxaban appears to be effective and safe as extended-phase anticoagulation in patients with CAT. The mean treatment period was 3-times the standard 6-month course.